Research and Markets: DRG Insight: Colorectal Cancer (G7)

DUBLIN--(BUSINESS WIRE)-- Research and Markets ( has announced the addition of Decision Resources, Inc's new report "DRG Insight: Colorectal Cancer (G7)" to their offering.

DRG Insights takes the most relevant information and insights from across our portfolio for BioPharma and Med-Tech products and delivers the insight heavy perspective that you need to generate better ideas and deliver more successful campaigns and initiatives. Colorectal cancer (CRC) is one of the most common forms of cancer and in 2010 was the fifth most common cancer-related death worldwide.

Over the next ten years the number of incident cases of CRC will increase as the aging population continues to expand and patients continue to be identified through screening efforts throughout the major markets.

Although in 2010 major-market sales of CRC treatments totaled more than $7 billion, reflecting robust sales of premium-priced products, interviewed experts express the demand for more treatments that address CRC patients' numerous unmet needs.

Key Topics Covered:

Executive Summary

Current Market Landscape

Etiology & Pathophysiology

Staging/Patient Segmentation

Select Drug Targets

Growth Drivers & Constraints

Key Metrics

Population Dynamics

Market Landscape

Current Therapies

Treatment Algorithms

Country Specific Decision Trees

Comparison of Key Agents

Expert Insight on Prescribing Trends

Importance of Drug Attributes in Prescribing Decisions

Pricing & Reimbursement

Factors Influencing Pharmacy Director Tier Placement Decisions

Accessibility and Cost Hurdles

Reimbursement Environment

Unmet Needs, Emerging Therapies

Near-term Outlook

Long-term Outlook

Important Endpoints in Prescribing Decisions,


2010 and 2010 sales and Market Share

For more information visit

Source: Decision Resources, Inc

Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology, Colon Cancer

Source: Research and Markets